Medical Xpress October 19, 2025
Men whose prostate cancer returns after surgery or radiation therapy may now benefit from a new drug combination shown in clinical trials to cut the risk of death by more than 40%.
The combination therapy, which adds a drug called enzalutamide to commonly prescribed hormone therapy, reduced deaths in patients with recurrent prostate cancer after surgery or radiation for whom other treatments are no longer an option.
The trial results were published in The New England Journal of Medicine with simultaneous presentation during the European Society for Medical Oncology Congress (ESMO) Oct. 19 in Berlin.
“After initial treatment, some patients see their prostate cancer come back in an aggressive way and are at risk for their disease to spread quickly,”...
Today's Sponsors
Today's Sponsor